Autres langues AstraZeneca PLC

Actions

AZN

GB0009895292

Produits pharmaceutiques

Marché Fermé - London S.E. 17:35:03 03/09/2026			Varia. 5j.	Varia. 1 janv.
12 146,00 ^GBX	+1,42%		+0,26%	-11,92%

03/09	Les actions britanniques progressent, portées par le rallye obligataire et l'appétit pour le risque	RE
03/09	AstraZeneca maintenu à l'Achat : Berenberg souligne l'imminence des résultats sur la BPCO	MT

Autres langues

03/09	UK stocks rise as bond rally lifts risk sentiment
03/09	AstraZeneca Kept at Buy as Berenberg Notes Upcoming COPD Data Readout
03/09	UK stocks recover as bond rally lifts risk sentiment
03/09	Morning Meeting: Comienzo sombrío de la temporada bursátil de otoño
02/09	Owkin signs AI drug discovery deal with Boehringer for cancer, immunology
02/09	AstraZeneca finalizes the acquisition of global rights to Zegfrovy
01/09	London Shares Fall Amid Shop Price Inflation, Renewed US-Iran Tensions
01/09	European Stocks Close Mostly Lower in Tuesday Trading; Euro Area Inflation Surges in August
01/09	Global markets live: Amazon, Tesla, Nvidia, Apple, Eli Lilly…
01/09	Astrazeneca plc and Dizal Pharmaceutical Co., Ltd Complete Global License Agreement for Oral Egfr Inhibitor Zegfrovy for Lung Cancer
01/09	Hutchmed "thrilled" by positive phase 3 trial results
01/09	Global pharma companies that have publicly announced Trump drug pricing agreements
01/09	AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
01/09	AstraZeneca unveils Zegfrovy deal, lung trial win and Enhertu approval
01/09	WINNERS & LOSERS: Oil majors rise, miners slide on lower metals prices
01/09	AstraZeneca Reports 'Meaningful Improvement' in Phase 3 Study of Lung Cancer Patients
01/09	Astrazeneca and Hutchmed Report Positive Results for Tagrisso Plus Orpathys in Sanovo Phase Iii Trial in 1St-Line Met-Overexpressing Egfr-Mutated Lung Cancer
01/09	AstraZeneca Says Breast Cancer Combo Approved in EU; Completes Acquisition of License for Lung Cancer Treatment
01/09	EU lässt Brustkrebsmedikament von Astrazeneca und Daiichi Sankyo zu
01/09	Astrazeneca plc Announces Appointment of Wan Ling Martello as Non-Executive Director and Audit Committee Member, Effective September 1, 2026
01/09	Daiichi Sankyo And AstraZeneca Receive Approval For Enhertu Plus Pertuzumab As First-Line Treatment For HER2 Positive Metastatic Breast Cancer In The EU
01/09	AstraZeneca, Daiichi Sankyo Get New EU Approval for Breast Cancer Drug
01/09	UK Stocks-Factors to watch on September 1
01/09	UK house prices subdued; Bunzl lifts outlook
01/09	AstraZeneca-Hutchmed drug combination shows promise in advanced lung cancer study